Pharmaceutical Strategy Analysis l Report Store l Pharma Intelligence

Ovarian Cancer Pricing, Reimbursement, and Access

Ovarian cancer medicines have traditionally been subject to low restrictions, as most patients usually start and remain on inexpensive platinum-based therapies. However, beginning with the launch of vascular endothelial growth factor inhibitor Avastin, followed by poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza, payers are seeing an uptick in spend for the indication.

Strategy analysis

Ovarian Cancer Pricing, Reimbursement, and Access

Crohn’s Disease and Ulcerative Colitis Pricing, Reimbursement, and Access

Chronic Heart Failure Pricing, Reimbursement, and Access

Digital Pharma: Are We Nearly There?

Renal Cell Cancer Pricing, Reimbursement, and Access

Value-Based Reimbursement in the US

Bladder Cancer Pricing, Reimbursement, and Access

Datamonitor Healthcare Strategy: Gene Therapy Pipeline and Portfolio Analysis

Datamonitor Healthcare Strategy: Gene Therapy Commercialization – Opportunities and Barriers

First-In-Class Therapies’ Shrinking In-Class Monopolies

ISPOR Europe 2018 Whitepaper

New Pharma Models for a New Healthcare Era

Biosimilar Commercial Strategies and Tactics

Key Potential Drug Launches in 2020

2019 Biomedtracker / Datamonitor Healthcare Post-AAN Report